I-many Announces 6.5 Release of ContractSphere

EDISON, N.J.--(BUSINESS WIRE)--I-many, Inc. (NASDAQ:IMNY), the leading provider of contract management software and services for the enterprise, today announced December 2008 availability for the 6.5 release of ContractSphere^®.

I-many’s ContractSphere provides a comprehensive set of contract and commerce management solutions that enable customers to track the contract and its terms, the money from contract to cash and the product from the time it leaves the manufacturing facility to the time it is dispensed. I-many’s ContractSphere includes business solutions for contract management, revenue management and adjudication, demand management and contract analytics. The integration of these business solutions within ContractSphere uniquely enables customers to realize greater return on investment and strongly address critical compliance issues.

The 6.5 release brings new support for contract analytics. This fills a significant void in a pharmaceutical company’s ability to analyze a prospective contract. It provides the insight to optimize terms, conditions, return on investment and discount levels. Contract analytics also provides a view of these activities in the context of best price thus providing a powerful capability previously unavailable in the industry.

"ContractSphere has always been our vision for the future – today we have realized the first step with an integrated offering for Life Sciences," said John Rade, president and CEO, I-many. “ContractSphere now enables the industry’s most advanced vision for contract management and trade operations. This integration enables capability and return on investment not before possible across a broad spectrum of key business decisions. We are the first and only company offering this capability for Life Sciences customers.”

"ContractSphere now provides very strong support for compliance – we have the strongest deployable solution today to support the coming audits for Medicare part D-related transactions,” said Chris Biddle, vice president of strategy for life sciences, I-many. “This issue will affect all pharmaceutical companies, both branded and generic, operating in the United States today. Only CARS (NG) and Validata provide the complete, transactional history from the RX level through claim payment, which will absolutely be required of manufacturers during an audit. We believe that the audit process will follow the same conventions as those historically performed for Medicaid and Best Price.”

About I-many

I-many (NASDAQ:IMNY) is the leading provider of contract management software and services for the enterprise. With hundreds of companies across 21 industries worldwide, I-many is enabling businesses to manage the entire contract life cycle, from pre-contract processes and contract management to active compliance, contract optimization, demand channel visibility and control. The result is an end-to-end solution that provides greater levels of insight into contract performance, allowing companies to improve profitability and achieve a measurable return on investment. For more information, please visit www.imany.com.

This news release contains forward-looking statements, and actual results may vary from those expressed or implied herein. Factors that could affect these results include the risk of unforeseen technical or practical impediments to planned software development and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission.